What is MAP?
Nonprofit drug distributors have played an important role in solving access to medicine challenges in developing countries around the world for many years.
IMAP has been created in response to the lack of access to essential CF medicines due to excessive pricing or monopoly exploitation from patent holders and profit-driven distributors. The high prices of many CF medicines have resulted in a lack of access in many countries across the Middle East and Africa. The MECFA Access Program, MAP, was created to help MECFA member countries gain access to affordable CF drugs.
What will MAP do for patients?
MECFA works with CF drug companies to negotiate the lowest prices possible for essential CF drugs. As a charity, we appeal to companies' philanthropic side and work in collaboration to ensure our CF patients have access tho their life-saving drugs.
We partner with health ministries to register a short list of essential CF drugs and ensure access to these drugs at affordable prices.
How does MAP work?
MECFA works to encourage health ministries to supply a basic list of CF drugs. Our list includes inhaled tobramycin, Dnase, CF vitamins, Colistin, and CF specific nebulizers.
Through the MAP we have created a network of pharmaceutical partners who provide MECFA qualifying member countries at production costs.
To learn if your country qualifies email us at